16:03:24 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-18 Bokslutskommuniké 2024
2024-11-07 Kvartalsrapport 2024-Q3
2024-07-18 Kvartalsrapport 2024-Q2
2024-05-08 Ordinarie utdelning ENZY 0.00 SEK
2024-05-07 Årsstämma 2024
2024-04-25 Kvartalsrapport 2024-Q1
2024-02-16 Bokslutskommuniké 2023
2023-11-07 Kvartalsrapport 2023-Q3
2023-07-18 Kvartalsrapport 2023-Q2
2023-05-05 Ordinarie utdelning ENZY 0.00 SEK
2023-05-04 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2022-11-02 Kvartalsrapport 2022-Q3
2022-07-19 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning ENZY 0.00 SEK
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-28 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-02 Kvartalsrapport 2021-Q3
2021-10-18 Extra Bolagsstämma 2021
2021-07-16 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning ENZY 0.00 SEK
2021-05-05 Årsstämma 2021
2021-04-29 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-07-16 Kvartalsrapport 2020-Q2
2020-05-06 Ordinarie utdelning ENZY 0.00 SEK
2020-05-05 Kvartalsrapport 2020-Q1
2020-05-05 Årsstämma 2020
2020-02-13 Bokslutskommuniké 2019
2019-11-05 Kvartalsrapport 2019-Q3
2019-07-17 Kvartalsrapport 2019-Q2
2019-05-08 Ordinarie utdelning ENZY 0.00 SEK
2019-05-07 Årsstämma 2019
2019-05-07 Kvartalsrapport 2019-Q1
2019-02-19 Bokslutskommuniké 2018
2018-10-31 Kvartalsrapport 2018-Q3
2018-07-17 Kvartalsrapport 2018-Q2
2018-04-27 Ordinarie utdelning ENZY 0.00 SEK
2018-04-26 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-14 Bokslutskommuniké 2017
2017-11-01 Kvartalsrapport 2017-Q3
2017-07-20 Kvartalsrapport 2017-Q2
2017-04-21 Ordinarie utdelning ENZY 0.00 SEK
2017-04-20 Kvartalsrapport 2017-Q1
2017-04-20 Årsstämma 2017
2017-02-16 Bokslutskommuniké 2016
2016-12-19 Extra Bolagsstämma 2016
2016-11-03 Kvartalsrapport 2016-Q3
2016-07-18 Kvartalsrapport 2016-Q2
2016-05-25 Årsstämma 2016
2016-04-22 Ordinarie utdelning ENZY 0.00 SEK
2016-04-18 Kvartalsrapport 2016-Q1
2016-02-16 Bokslutskommuniké 2015
2015-10-20 Kvartalsrapport 2015-Q3
2015-07-21 Kvartalsrapport 2015-Q2
2015-04-22 Ordinarie utdelning ENZY 0.00 SEK
2015-04-21 Årsstämma 2015
2015-04-21 Kvartalsrapport 2015-Q1
2015-02-17 Bokslutskommuniké 2014
2014-12-19 Extra Bolagsstämma 2014
2014-10-21 Kvartalsrapport 2014-Q3
2014-07-22 Kvartalsrapport 2014-Q2
2014-05-20 Ordinarie utdelning ENZY 0.00 SEK
2014-05-19 Årsstämma 2014
2014-05-19 Kvartalsrapport 2014-Q1
2014-02-04 Bokslutskommuniké 2013
2013-11-13 Kvartalsrapport 2013-Q3
2013-08-22 Kvartalsrapport 2013-Q2
2013-05-21 Kvartalsrapport 2013-Q1
2013-05-07 Ordinarie utdelning ENZY 0.00 SEK
2013-05-06 Årsstämma 2013
2013-02-15 Bokslutskommuniké 2012
2012-11-22 Kvartalsrapport 2012-Q3
2012-08-23 Kvartalsrapport 2012-Q2
2012-06-04 15-7 2012
2012-05-24 Kvartalsrapport 2012-Q1
2012-05-16 Kvartalsrapport 2012-Q1
2012-04-19 Ordinarie utdelning ENZY 0.00 SEK
2012-04-18 Årsstämma 2012
2012-02-29 Kvartalsrapport 2011-Q3
2012-02-29 Bokslutskommuniké 2011
2011-12-22 Kvartalsrapport 2011-Q2
2011-09-29 Kvartalsrapport 2011-Q1
2011-09-16 Ordinarie utdelning ENZY 0.00 SEK
2011-09-15 Årsstämma 2011

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Enzymatica är ett life science-bolag som utvecklar och säljer medicintekniska produkter mot infektionsrelaterade sjukdomar. Produkterna baseras på barriärteknologi, som inkluderar marina enzymer. Bolagets första produkt är ColdZyme® Munspray som kan förhindra förkylning, och kan förkorta sjukdomsperioden. Produkten har lanserats på flertalet marknader och strategin är att expandera till fler marknader via samarbetspartners. Huvudkontor ligger i Lund.
2022-02-17 08:30:00

Significant Other events in Q4
events in Q4

  • The · Enzymatica's partner Sanofi received approval from the
Extraordinary health authorities in Mexico (Cofepris) and Turkey (TITCK),
General which enabled the launch of ColdZyme in these markets.
Meeting on · In December, ColdZyme was approved as a "Natural Health
October 18, Product" by the Canadian authorities (Health Canada).
2021, resolved · In December, the Patent Office in Mexico issued a
to approve an preliminary ruling that it intends to grant Enzymatica a
incentive patent for the cod trypsin that is one of the key components
program for in ColdZyme. Final approval is expected to be granted during
CEO Claus the first half of 2022 and the patent will be valid until
Egstrand 2036.
through an · Through the agreement with STADA, in the fourth quarter
employee Enzymatica gained sales to Finland, Poland, the Balkans, the
option plan, a Netherlands, Greece, and to six new markets: Cyprus,
directed issue Moldavia, Azerbaijan, Georgia, Armenia and Mongolia.
of warrants
and a transfer
of warrants.
  • On
November 2,
2021, the
Board of
Directors
reached a
decision on
financial
targets for
the company.
Net sales in
2026 will
amount to at
least SEK 600
million with
an EBIT margin
of at least 28
%.
  • No
significant
events were
reported after
the end of the
quarter.

Q4 January-December
  • Net sales reached SEK 18.7 (42.3) · Net sales reached SEK 57.2
million. (111.2) million.
  • The result for the period was SEK -10.8 · The result for the period was
million (-0.3). SEK -45.4 million (-13.2).
  • Earnings per share, basic and diluted, · Earnings per share, basic and
were SEK -0.07 (0.00). diluted, were SEK -0.31 (-0.09).
  • Cash flow from operating activities for · Cash flow from operating

the period totalled SEK -6.1 (-8.2) million. activities for the period
totalled
SEK -35.4 (-10.7) million.

  • Net debt totalled SEK -29.0 (
-9.2) million.

"The pandemic has laid the foundation for changing consumer behaviours that will benefit Enzymatica, and during Q4/2021 we noted that the cold remedy market continued to recover in many of our key markets. Fourth quarter sales and earnings were in line with our expectations and with the favourable trends we now see in the market, we are optimistic about 2022", said Claus Egstrand, CEO.

The full year-end report is available on: www.enzymatica.se/se/investerare/finansiella-rapporter

This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on 17 February 2022.

For more information, please contact:

Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com

Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 (0) 708 55 11 85 | Email: stefan.olsson@enzymatica.com

    

Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market. For more information, please visit www.enzymatica.se. Enzymatica's Certified Adviser is Erik Penser Bank. Tel: +46 8 463 83 00 Email: certifiedadviser@penser.se.